Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendations
NICE has recommended rucaparib as an option for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if:
-
it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or
-
it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because:
-
NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or
-
it is contraindicated or not tolerated, and
-
-
the company provides rucaparib according to the commercial arrangement.
These recommendations are not intended to affect treatment with rucaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.
Eligible population for rucaparib
Table 1 shows the population who are eligible for rucaparib and the number of people who are expected to have rucaparib in each of the next 5 years.
| Eligible population and uptake | Current practice | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|---|
|
People eligible for rucaparib |
860 |
870 |
880 |
890 |
900 |
900 |
|
Uptake for rucaparib (%) |
0 |
30 |
50 |
50 |
50 |
50 |
|
People starting treatment each year |
0 |
260 |
440 |
445 |
450 |
450 |
|
People continuing treatment from previous years |
0 |
0 |
260 |
700 |
890 |
890 |
|
People having rucaparib each year |
0 |
260 |
700 |
1,145 |
1,340 |
1,340 |
Treatment options for the eligible population
The comparator treatments for rucaparib were:
-
olaparib plus bevacizumab, bevacizumab alone and routine surveillance for the BRCA mutation-negative HRD‑positive population
-
bevacizumab alone and routine surveillance for the BRCA mutation negative HRD‑negative population.
Niraparib is a treatment option that was not included as a comparator because it is not recommended in routine commissioning. But experts, the company and the committee considered that it would be the main alternative to rucaparib in clinical practice because the HRD‑negative population can only have rucaparib if bevacizumab is not an option.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The company has a commercial arrangement. This makes rucaparib available to the NHS with a discount.
Users can input the confidential price of rucaparib and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Table 2 shows the impact on capacity activity in each of the next 5 years.
| Capacity impact | Current practice | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|---|
|
Number of administration appointments |
9,300 |
9,670 |
10,100 |
10,500 |
10,630 |
10,730 |
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
Table 3 Key information| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
02G cancers and tumours, gynaecological |
| Commissioner |
NHS England |
| Providers |
NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy and should be read with it. See terms and conditions and on the NICE website.
ISBN: 978-1-4731-6970-8
This page was last updated: